Clinical hold for PepGen's myotonic dystrophy program halts march to the clinic
The FDA imposed a clinical hold on PepGen’s IND for a drug for myotonic dystrophy type 1 (DM1), slowing down the company’s plans to bring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
